Abeona Therapeutics Incの発行済株式数
Abeona Therapeutics Incの発行済株式数は何ですか。
Abeona Therapeutics Incの発行済株式数は43.314Mです。
発行済株式数の定義は何ですか。
発行済株式数は、投資家によって承認、発行、購入され、保有されている法人または金融資産のすべての株式である。
Shares outstanding includes all stock held by investors including both common shares held by the public and restricted shares owned by the company's internal managements. Shares outstanding have rights and represent an ownership in the corporation by the person who holds the shares. They are distinguished from treasury shares, which are shares held by the corporation itself and have no exercisable rights. Shares outstanding plus treasury shares together amount to the number of issued shares.
Shares outstanding can be calculated as either basic or fully diluted. The basic count is the current number of shares. Dividend distributions and voting in the general meeting of shareholders are calculated according to this number. The fully diluted shares outstanding count, on the other hand, includes diluting securities, such as warrants, capital notes or convertibles. If the company has any diluting securities, this indicates the potential future increased number of shares outstanding. A company's market capitalization is calculated by multiplying the price of one of its shares by the total number outstanding shares a company has issued.
NASDAQのセクタHealth Careにおける発行済株式数の企業と比べるAbeona Therapeutics Inc
Abeona Therapeutics Incは何をしますか。
abeona therapeutics inc. (nasdaq: $abeo), is a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for life-threatening rare genetic diseases. abeona was forged from the company’s close collaborations with key stakeholders all dedicated to transforming new biotechnology insights into breakthrough treatments for rare diseases. abeona's lead programs include abo-102 (aav-sgsh), an adeno-associated virus (aav) based gene therapy for sanfilippo syndrome type a (mps iiia) and eb-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (rdeb). abeona is also developing abo-101 (aav-naglu) for sanfilippo syndrome type b (mps iiib), abo-201 (aav-cln3) gene therapy for juvenile batten disease (jncl), abo-202 (aav-cln1) for treatment of infantile batten disease (incl), eb-201 for epidermolysis bullosa (eb), abo-301 (aav-fancc) for fanconi anemia (fa) disorder and abo-302 using a novel crispr/cas9-based gene editing approach to gene t
Abeona Therapeutics Incと類似の発行済株式数
- BASF Indiaの発行済株式数は43.285Mです。
- BASF Indiaの発行済株式数は43.286Mです。
- United Insurance Corpの発行済株式数は43.288Mです。
- Sanghvi Moversの発行済株式数は43.288Mです。
- Sanghvi Moversの発行済株式数は43.288Mです。
- Jay Bharat Marutiの発行済株式数は43.300Mです。
- Abeona Therapeutics Incの発行済株式数は43.314Mです。
- Auswide Bank Ltdの発行済株式数は43.316Mです。
- S&W Seed Coの発行済株式数は43.344Mです。
- Western Asset Managed Municipals Fund Incの発行済株式数は43.368Mです。
- Majescoの発行済株式数は43.373Mです。
- Majescoの発行済株式数は43.373Mです。
- Concord Medical Servicesの発行済株式数は43.417Mです。